Free Trial
OTCMKTS:JAPAY

Japan Tob 5/7/2025 Earnings Report

Japan Tob logo
$14.31 +0.10 (+0.70%)
As of 07/11/2025 03:58 PM Eastern

Japan Tob EPS Results

Actual EPS
$0.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Japan Tob Revenue Results

Actual Revenue
$5.42 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Japan Tob Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Japan Tob's next earnings date is estimated for Thursday, July 31, 2025, based on past reporting schedules.

Conference Call Resources

Japan Tob Earnings Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Japan Tob Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Japan Tob? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Japan Tob and other key companies, straight to your email.

About Japan Tob

Japan Tob (OTCMKTS:JAPAY)acco Inc. (OTCMKTS:JAPAY) is a Tokyo‐based international tobacco company with roots dating back to the enactment of Japan’s government monopoly in 1898 and its subsequent privatization in 1985. Since its establishment, the company has expanded beyond its domestic origins to become one of the world’s largest tobacco manufacturers. Japan Tobacco operates through two core business segments: its domestic tobacco operations in Japan and its international arm, Japan Tobacco International (JTI), which oversees production, marketing and distribution outside of Japan.

The company’s main business revolves around the manufacture and sale of combustible cigarettes, smokeless tobacco products and innovative reduced‐risk products. Its flagship brands include Mevius (formerly Mild Seven), Winston (under license), Camel (in select markets), LD and Benson & Hedges. In recent years, Japan Tobacco has also invested in next‐generation alternatives such as the Ploom series of heat‐not‐burn devices and nicotine pouches under the “Logic” brand, reflecting a strategic shift toward harm‐reduction offerings.

Beyond tobacco, Japan Tobacco maintains operations in pharmaceuticals and processed foods, although these divisions represent a smaller proportion of overall revenues. The pharmaceutical unit focuses on ethical drugs and over‐the‐counter remedies, leveraging the company’s research capabilities to address conditions such as respiratory and cardiovascular diseases. Its processed food business produces snacks and culinary ingredients for the Japanese market, drawing on a long history of food manufacturing expertise.

With a presence in more than 130 countries and regions, Japan Tobacco leverages a global supply chain and extensive distribution network. The company’s leadership team, headed by a board of directors and chief executives with deep experience in consumer goods and regulatory environments, has pursued growth through strategic acquisitions—most notably the 2007 purchase of the Gallaher Group—and ongoing investment in next‐generation tobacco and related products. This approach underscores Japan Tobacco’s commitment to sustaining its market position amid evolving industry dynamics.

View Japan Tob Profile

More Earnings Resources from MarketBeat